Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside

Activity Overview

The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside Industry Supported Symposium pbeing resented at the WAGO 2026 Annual Meeting on Thursday, June 18, 2026.

Course Description

Platinum‑resistant ovarian cancer (PROC) remains a major therapeutic challenge due to modest survival outcomes and frequent treatment resistance. This CME session delivers a science‑forward, methodologic update designed to help clinicians interpret evolving evidence and educate the audience on thoughtful practice-based approach.  Faculty will cover the current treatment landscape and survival benchmarks; mechanisms of resistance that inform next‑generation strategies; a masterclass in interpreting Phase 3 data (design, endpoints, and external validity); and equity and access considerations including biomarker testing logistics, clinical trial access, and shared decision‑making. Through a moderated panel, attendees will contextualize new evidence, anticipate how pending regulatory decisions may impact care, and identify research implications. The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: Corcept Therapuetics
 

Target Audience

Gynecologic and medical oncologists, oncology researchers, clinical trial coordinators, advanced practice providers, and other healthcare professionals involved in the management of ovarian cancer.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate increased knowledge regarding:
  • Summarize the current U.S. treatment landscape and unmet needs in platinum‑resistant ovarian cancer, including survival benchmarks and patterns of progression.
  • Explain key biological drivers of resistance (e.g., DNA damage repair, replication stress, microenvironmental/immune factors) and how they inform therapeutic rationale and trial design.
  • Critically interpret Phase 3 evidence (HRs, PFS/OS hierarchy, censoring, subgroup analyses, external validity) to guide evidence‑based practice.
  • Apply biomarker information (e.g., FRα, BRCA, HRD) pragmatically—recognizing testing access, turnaround, and interpretation challenges—without referencing specific products.
  • Engage in case‑based decision‑making and articulate how pending FDA decisions and guideline updates may shape future patient selection and sequencing.
 

Moderator

Katherine Fuh, MD
University of California – San Francisco
 

Faculty

Christine Walsh, MD
University of Colorado Hospital, Anschutz Cancer Pavilion
Shannon Westin, MD
MD Anderson Cancer Center
 

Agenda

Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside, an Industry Supported Symposium presented at the WAGO 2026 Annual Meeting

CME for this Industry Supported Symposium is provided by The GOG Foundation, Inc. Credit is available only for live, in-person attendance and completion of the activity evaluation. CME credit will not be awarded for virtual attendance or viewing of recorded materials.
Register Today
12:30 pm – 12:40 pm PT
Welcome, Needs, and Pre‑Assessment
Katherine Fuh, MD, PhD, University of California San Francisco (UCSF)
 
12:40 pm – 1:00 pm PT
Current U.S. Management & Unmet Needs in PROC
Christine Walsh, MD, University of Colorado Hospital, Anschutz Cancer Pavilion
 
1:00 pm – 1:20 pm PT
Why Resistance Happens: Clinical Implications of Tumor Biology
Shannon Westin, MD, MD Anderson Cancer Center
 
1:20 pm – 1:40 pm PT
Interpreting New Phase 3 Evidence: A Methodology Masterclass
All Faculty
 
1:40 pm – 1:55 pm PT
Case‑Based Application
All Faculty
 
1:55 pm – 2:00 pm PT
Panel Q&A, Post‑Assessment
All Faculty
 
 

Continuing Education

In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement

The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians. The GOG Foundation, Inc. designates this in-person activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. Participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the online evaluation that will be sent to all registered participants who provide a valid email address and attend the activity. Participants who complete the educational activity and evaluation will receive a certificate of credit. In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information. Faculty Disclosures
  • Katherine Fuh, MD, PhD, University of California San Francisco (UCSF), San Francisco, CA
  • Christine Walsh, MD, University of Colorado Hospital, Anschutz Cancer Pavilion
  • Shannon Westin, MD, MD Anderson Cancer Center